Seat­tle Ge­net­ics? Not any­more. The biotech has short­ened its name to Seagen to il­lus­trate glob­al ex­pan­sion

Would a Seat­tle Ge­net­ics by any oth­er name smell as sweet? We’re about to find out.

The biotech an­nounced Thurs­day it’s chang­ing its name to Seagen, cap­ping off what’s been a 12-month pe­ri­od in which it closed a $4.5 bil­lion deal with Mer­ck and saw two drugs get FDA ap­proval. Seagen is al­so keep­ing the same Wall Street tick­er — $SGEN.

CEO Clay Sie­gall said the com­pa­ny made the change to rep­re­sent its ex­pand­ing glob­al op­er­a­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER